Trial Profile
A Phase I Trial of BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Mar 2022
Price :
$35
*
At a glance
- Drugs Alpelisib (Primary) ; Exemestane; Letrozole
- Indications Advanced breast cancer
- Focus Adverse reactions
- 01 Mar 2022 Status changed from active, no longer recruiting to completed.
- 09 Mar 2021 Planned End Date changed from 1 May 2020 to 1 Apr 2022.
- 09 Mar 2021 Planned primary completion date changed from 1 May 2020 to 1 Apr 2022.